Pharmaceuticals company RPG Life Sciences announced Q1FY26 results RPG Lifesciences revenue recorded 2.1% YoY increase in sales (18.1% Q-o-Q growth) along with a healthy EBITDA margin of 24.1%. Profit before tax remained largely in line with previous year stood at Rs 35.4 crore in this year vs. Rs 36.0 crore in previous year Year on Year Revenue from Operations stood at Rs 168.9 crore vs. Rs 165.4 crore Ashok Nair, Managing Director, RPG Life Sciences said, “In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence. Our Domestic Formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach. We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach.” “We are actively exploring inorganic growth opportunities across both formulations and APIs to further accelerate our growth trajectory and create lasting value for all stakeholders,” added Nair. Result PDF
Conference Call with RPG Life Sciences Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company RPG Life Sciences announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations: Rs 143.09 crore up from Rs 126.99 crore, Up by 13% YoY. PBT before exceptional items: Rs 25.00 crore up from Rs 17.74 crore, Surges 41% YoY. FY25 Financial Highlights: Revenue from operations: Rs 653.43 crore up from Rs 582.05 crore, Up by 12% YoY. PBT before exceptional items: 150.28 crore up from Rs 117.84 crore, Surges 28% YoY. EBITDA Margin Expanding from 23.3% to 26.4% YoY. Yugal Sikri, Managing Director, RPG Life Sciences, said: “In Q4FY25, the overall performance of the Company continued to be strong. Revenue and PBT before exceptional items grew by 13% and 41% respectively YoY. The full year EBITDA margin surged from 23.3% to 26.4% YoY, retaining its upward trajectory YoY for the last 6 years. Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market. Thanks to our five pillar strategy, we are building brands, portfolios and therapies; increasing sales force productivity and nurturing strategic business assets. We are quite on course in shaping our International Formulations and API businesses to emerge as second and third growth engines by way of modernisation of both our API and Formulations plants, setting up new R&D; units, developing a strong product pipeline, by infusion of significant capex. The International Formulations business is registering healthy double-digit profitable growth, and the API business is also showing promising profitable growth. Our structural approach of cost optimisation has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted YoY margin expansion trajectory. The Company has built sizeable cash surplus of ~Rs 168 crore from operations as a result of continued remarkable business performance. Additional cash generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant has further augmented the pool to ~Rs 266 crore. We are actively pursuing inorganic opportunities to accelerate business growth. On the back of continued robust performance, The Board of Directors has recommended highest ever dividend of 250% plus a special dividend of 50% on the face value of Rs 8 each for FY25, subject to the approval of shareholders at the ensuing Annual General Meeting, thus maintaining an upward trajectory of dividend for the last 6 years.” Result PDF
Pharmaceuticals company RPG Life Sciences announced Q3FY25 results Revenue from operations registered a growth of 12% YoY and a flat growth QoQ for Q3FY25. EBITDA Margin Jumps from 25.9% to 30.4% YoY. PBT before exceptional items by 32% YoY and by 11% QoQ for Q3FY25. Yugal Sikri, Managing Director, RPG Life Sciences. said: “In Q3FY25, the overall performance of the company continued to be strong. Revenue and PBT grew by 12% and 32% respectively YoY. EBITDA margin surged from 25.9% to 30.4% YoY retaining its upward trajectory YoY for the last more than 5 years. The Company continues to remain debtfree. Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market basis the five pillar strategy – product portfolio rejuvenation, building strategic brand/portfolio assets, sales force excellence and productivity enhancement, customer engagement through medico-marketing initiatives and continued cost efficiency drive. We are now shaping our International Formulations and API businesses to emerge as second and third growth engines. For this to happen, while we are on course to modernize both our API and Formulations plants - by infusion of significant capex, our modernized R&D; laboratories are also working to build a smart product pipeline. The International Formulations business is now registering healthy double-digit growth, and the API business is also showing promising growth. Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted YoY margin expansion trajectory. Cash that would be generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant will add to our existing cash surplus which we are actively working to deploy gainfully for business expansion.” Result PDF
Conference Call with RPG Life Sciences Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company RPG Life Sciences announced Q1FY25 results: Financial Highlights: YoY Revenue from operations: Rs 165.42 crore – up from Rs 147.78 crore YoY PBT: Rs 36.00 crore – up from Rs 29.77 crore The Company maintained an upward trajectory in EBITDA margin, which improved from 23.0% to 25.1% YoY. Yugal Sikri, Managing Director, RPG Life Sciences said, “In Q1FY25, the overall performance of the Company continued to be strong. Revenue and PBT grew by 12% and 21% respectively YoY. Retaining its 5-year upward trajectory, the EBITDA margin crossed the 25% mark (25.1% up from 23.0% last year). Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market - building some of our iconic “Textbook” brands like Naprosyn into megabrands through a comprehensive life cycle management program, shaping one successful product into a multi-product portfolio by leveraging our existing strong customer franchise, building the futuristic portfolio of MABs into a formidable product segment through multibranding strategy, replicating our smart and successful Rheumatology portfolio entry strategy to enter more specialties like Gastro and Derma, and deploying digital and productivity enhancement measures to ensure consistent salesforce productivity gains year-after-year. We are now shaping our International Formulations and API businesses to emerge as second and third growth engines.For this to happen, while we are on course to modernize both our API and Formulations plants - by infusion of significant capex, our modernized R&D; laboratories are also working to build a smart product pipeline. The International Formulations business is now registering healthy double-digit growth and the API business is also showing promising growth. Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted YoY margin expansion trajectory." Result PDF
Pharmaceuticals company RPG Life Sciences announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue Growth: RPG Life Sciences reported a YoY revenue increase for the Q4FY24, with revenue from operations going up from Rs 118.49 crore to Rs 126.99 crore, marking a 7% growth. Profit Before Tax (PBT): The company experienced a significant jump in PBT of 28% YoY for Q4FY24, climbing from Rs 13.81 crore to Rs 17.74 crore. EBITDA Margin Expansion: There has been a notable improvement in EBITDA margins, from 15% to 17.6% YoY for Q4. FY24 Financial Highlights: Revenue Growth: The full-year performance was also strong, with revenues increasing by 14% to Rs 582.05 crore for FY24, up from the previous year's Rs 512.81 crore. Profit Before Tax (PBT): For the full fiscal year, PBT surged by 29%, with figures reaching Rs 117.84 crore compared to the earlier Rs 91.68 crore. EBITDA Margin Expansion: A YoY rise for the full year from 21.0% to 23.3%. Yugal Sikri, Managing Director, RPG Life Sciences said, “In Q4FY24, the overall performance of the Company continued to be strong. Revenue and PBT grew by 7% and 28% respectively YoY. The EBITDA margin retained its 5-yearlong upward trajectory growing from 21.0% to 23.3% YoY. The Company continues to remain debt-free. We are well on course in executing all the tenets of our distinctive and smart transformation agenda to achieve our strategic goal of consistent, healthy, and profitable growth. Our top priority, Domestic Formulations, the biggest contributor to the Company’s business, recorded robust growth in both value and volume - significantly and consistently ahead of the marketbased on its 5 pillar-growth strategy. The comprehensive smart life cycle management program is shaping some of our ‘textbook’ legacy brands into mega brands and our niche specialty portfolio into mega portfolio. New launches in specialty and chronic therapies are helping us shape our Specialty business. We are now working on replicating our smart and successful Rheumatology portfolio entry strategy to enter other specialties like Gastro and Derma to emerge as future growth drivers of Domestic Formulations business. Our MABs portfolio continues to post robust performance. Salesforce productivity continues to register healthy upward momentum, assisted by smart deployment of digital. We are now shaping our International Formulations and API business basis their own 5 pillars, the key being plants modernization cum capacity expansion by infusion of capex and building a smart product pipeline to become strong futuregrowth drivers. The International Formulations business has been registering healthy double-digit growth. Modernization of our API Plant and building product pipeline, both currently underway, will make API also our third engine of growth. Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain 5-year uninterrupted YoY margin expansion trajectory for the past 5 consecutive years.” Result PDF